Gyre Therapeutics Reports Q1 Net Loss Amid Strategic Investments, Affirms Full-Year Guidance

summarizeSummary

Gyre Therapeutics reported a Q1 2026 net loss of $9.9 million, a reversal from prior year's profit, driven by increased operating expenses and acquisition costs, while affirming full-year revenue guidance and highlighting pipeline progress.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a net loss of $9.9 million for the three months ended March 31, 2026, compared to a net income of $3.7 million for the same period in 2025. Revenues increased slightly to $22.5 million from $22.1 million year-over-year.

• Operating Expenses Surge

  Total operating expenses rose to $31.9 million from $19.8 million in Q1 2025, driven by a 118% increase in R&D, a 30% rise in selling and marketing, and $2.5 million in transaction costs for the Cullgen acquisition.

• Full-Year Guidance Affirmed

  The company affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million, indicating management's confidence despite the Q1 loss.

• F351 NDA Granted Priority Review

  The New Drug Application (NDA) for F351 (hydronidone) for CHB-associated liver fibrosis was submitted to China's CDE in March 2026 and granted priority review designation.

auto_awesomeAnalysis

Gyre Therapeutics reported a significant net loss for Q1 2026, a notable shift from net income in the prior year, primarily driven by substantial increases in operating expenses. These expenses include higher research and development costs for F351 clinical trials and preclinical activities, increased selling and marketing for new product launches, and $2.5 million in transaction costs related to the recently completed Cullgen acquisition. While the financial performance for the quarter is negative, the company affirmed its full-year revenue guidance, suggesting management's confidence in future performance. Key pipeline advancements, such as the F351 NDA submission receiving priority review and the initiation of a new Phase 2/3 trial, indicate continued strategic execution and investment in growth areas following the Cullgen acquisition.